Region-specific dysregulation of glycogen synthase kinase-3β and β-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia

Bipolar Disorders

Volumn 17, Issue 2, 2015, Pages 160-171

  Pandey, Ghanshyam N ^a   Rizavi, Hooriyah S ^a   Tripathi, Madhulika ^a   Ren, Xinguo ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Bipolar illness; Cingulate gyrus; GSK 3 ; pGSK 3 ser 9; Postmortem brain; Prefrontal cortex; Schizophrenia; Temporal cortex; catenin

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, HUMAN; PHOSPHOPROTEIN; SERINE;

ADULT; ANTIBODY LABELING; ARTICLE; BIPOLAR DISORDER; CINGULATE GYRUS; CLINICAL ASSESSMENT; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUESTIONNAIRE; RNA ISOLATION; SCHIZOPHRENIA; TEMPORAL CORTEX; WESTERN BLOTTING; WNT SIGNALING PATHWAY; AGED; BRAIN; CASE CONTROL STUDY; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TEMPORAL LOBE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BETA CATENIN; BIPOLAR DISORDER; BRAIN; CASE-CONTROL STUDIES; FEMALE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; GYRUS CINGULI; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEINS; PHOSPHORYLATION; PREFRONTAL CORTEX; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA; SERINE; SIGNAL TRANSDUCTION; TEMPORAL LOBE; WNT SIGNALING PATHWAY;

EID: 84924262350     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12228     Document Type: Article

References (36)

1. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J 1998; 329: 209-223.
2. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781-810.
3. Moon RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 1997; 13: 157-162.
4. Peifer M. Regulating cell proliferation: as easy as APC. Science 1996; 272: 974-975.
5. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
6. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006; 7: 1421-1434.
7. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43: 1158-1164.
8. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-1330.
9. Ryves WJ, Dalton EC, Harwood AJ, Williams RSB. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord 2005; 7: 260-265.
10. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 2004; 29: 32-38.
11. Matigian N, Windus L, Smith H et al. Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. Mol Psychiatry 2007; 12: 815-825.
12. Benedetti F, Bernasconi A, Lorenzi C et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 2004; 355: 37-40.
13. Pandey GN, Ren X, Rizavi HS, Dwivedi Y. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment. J Psychiatr Res 2010; 44: 143-148.
14. Nadri C, Kozlovsky N, Agam G, Bersudsky Y. GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res 2002; 112: 51-57.
15. Lesort M, Greendorfer A, Stockmeier C, Johnson GV, Jope RS. Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain. J Neural Transm 1999; 106: 1217-1222.
16. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000; 157: 831-833.
17. Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005; 57: 533-542.
18. Cotter D, Kerwin R, al-Sarraji S et al. Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental abnormality. NeuroReport 1998; 9: 1379-1383.
19. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004; 36: 131-137.
20. Beasley C, Cotter D, Khan N et al. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett 2001; 302: 117-120.
21. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 2001; 52: 101-105.
22. Nadri C, Dean B, Scarr E, Agam G. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res 2004; 71: 377-382.
23. Forlenza OV, Torres CA, Talib LL et al. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2011; 45: 220-224.
24. Feighner JP, Robins E, Guze SB, Woodruff RA Jr, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972; 26: 57-63.
25. Pandey GN, Dwivedi Y, Rizavi HS et al. GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide. Neurochem Res 2009; 34: 274-285.
26. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
28. Ren X, Rizavi HS, Khan MA, Dwivedi Y, Pandey GN. Altered Wnt signalling in the teenage suicide brain: focus on glycogen synthase kinase-3beta and beta-catenin. Int J Neuropsychopharmacol 2013; 16: 945-955.
29. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
30. Lachman HM, Pedrosa E, Petruolo OA et al. Increase in GSK3beta gene copy number variation in bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 259-265.
31. Zandi PP, Belmonte PL, Willour VL et al. Association study of Wnt signaling pathway genes in bipolar disorder. Arch Gen Psychiatry 2008; 65: 785-793.
32. Prickaerts J, Moechars D, Cryns K et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 2006; 26: 9022-9029.
33. Kozlovsky N, Amar S, Belmaker RH, Agam G. Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol 2006; 9: 337-342.
34. Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 2007; 10: 7-19.
35. Bhat RV, Budd SL. GSK3beta signalling: casting a wide net in Alzheimer's disease. Neurosignals 2002; 11: 251-261.
36. Chen RH, Ding WV, McCormick F. Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem 2000; 275: 17894-17899.